Jacek Kubica

Prof. Dr. Jacek Kubica

Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2018 in JAMA
Verified
Journal Article
Open access
PDF file
ENEliano P. Navarese
Eliano P. Navarese
JRJennifer G. Robinson
Jennifer G. Robinson
MKMariusz Kowalewski
Mariusz Kowalewski
Michalina KołodziejczakMichalina Kołodziejczak
Michalina Kołodziejczak
FAFelicita Andreotti
Felicita Andreotti
PGPaul A. Gurbel
Paul A. Gurbel
Quiz Ref ID Consistent evidence has shown that statins reduce total cardiovascular events, and that further lowering of low-density lipoprotein cholesterol (LDL-C) levels by intensifying statin therapy, adding ezetimibe, or adding a proprotein convertase subtilisin/kexin type 9 (PCSK9)-inhibiting monoclonal antibody provides incremental additional reduction in cardiovascular risk.1-6 However, there is less consistency in the magnitude of the reductions in individual mortality and cardiovascular end points among the various trials. Total and cardiovascular mortality benefits were observed in several placebo-controlled statin cardiovascular outcomes trials as well as in meta-analyses of statin trials.1,7-9 In contrast, no reduction in cardiovascular mortality was observed in 5-year trials of moderate- vs high-intensity statin therapy or in trials of ezetimibe or evolocumab added to background statin therapy.2,3,10-12 Understanding differences in treatment effects across clinical trials may influence estimates of treatment benefit, have an important effect on guideline recommendations and clinical trial design, and has already had a significant influence on cost-effectiveness analyses and accessibility decisions.13-15

7 July 2015 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
ENEliano Pio Navarese
Eliano Pio Navarese
Michalina KołodziejczakMichalina Kołodziejczak
Michalina Kołodziejczak
VSVolker Schulze
Volker Schulze
PGPaul A. Gurbel
Paul A. Gurbel
UTUdaya Tantry
Udaya Tantry
MKMalte Kelm
Malte Kelm
Guidelines recommend statins as first-line therapy for dyslipidemia. Monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new lipid-lowering approach. To assess the efficacy and safety of PCSK9 antibodies in adults with hypercholesterolemia. MEDLINE, PubMed Central, and Google Scholar; conference proceedings; and the ClinicalTrials.gov registry through 4 April 2015. Phase 2 or 3 randomized, controlled trials (RCTs) comparing treatment using PCSK9 antibodies with no anti-PCSK9 therapy in adults with hypercholesterolemia. Two investigators independently extracted data on study characteristics and lipid and clinical outcomes, and rated risk of bias of trials. Prespecified primary end points were all-cause and cardiovascular mortality. Twenty-four RCTs comprising 10 159 patients were included. Compared with no antibody, treatment with PCSK9 antibodies led to marked reductions in low-density lipoprotein cholesterol levels (mean difference, −47.49% [95% CI, −69.64% to −25.35%]; P < 0.001] and other atherogenic lipid fractions, and it reduced all-cause mortality (odds ratio [OR], 0.45 [CI, 0.23 to 0.86]; P = 0.015; heterogeneity P = 0.63; I2 = 0%) and cardiovascular mortality (OR, 0.50 [CI, 0.23 to 1.10]; P = 0.084; heterogeneity P = 0.78; I2 = 0%). The rate of myocardial infarction was significantly reduced with use of PCSK9 antibodies (OR, 0.49 [CI, 0.26 to 0.93]; P = 0.030; heterogeneity P = 0.45; I2 = 0%), and increases in the serum creatine kinase level were reduced (OR, 0.72 [CI, 0.54 to 0.96]; P = 0.026; heterogeneity P = 0.65; I2 = 0%). Serious adverse events did not increase with administration of PCSK9 antibodies. Results were derived from study-level data rather than patient-level data, and clinical outcome data are rare. PCSK9 antibodies seem to be safe and effective for adults with dyslipidemia. CRC 1116 Masterswitches in Myocardial Ischemia, German Research Council DFG.

1 April 2013 in The American Journal of Cardiology
Verified
Journal Article
Closed access
ENEliano Navarese
Eliano Navarese
ABAntonino Buffon
Antonino Buffon
FAFelicita Andreotti
Felicita Andreotti
MKMarek Kozinski
Marek Kozinski
NWNicky Welton
Nicky Welton
JKJacek Kubica
Jacek Kubica

21 October 2015 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JKJacek Kubica
Jacek Kubica
PAPiotr Adamski
Piotr Adamski
MOMałgorzata Ostrowska
Małgorzata Ostrowska
JSJoanna Sikora
Joanna Sikora
JKJulia Maria Kubica
Julia Maria Kubica
MKMarek Koziński
Marek Koziński
The currently available data indicate a drug–drug interaction between morphine and oral P2Y12 receptor inhibitors, when administered together. The aim of this trial was to assess the influence of infused morphine on pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite (AR-C124910XX) in patients with acute myocardial infarction. In a single-centre, randomized, double-blind trial, patients were assigned in a 1:1 ratio to receive intravenously either morphine (5 mg) or placebo, followed by a 180 mg loading dose of ticagrelor. Pharmacokinetics was determined with liquid chromatography tandem mass spectrometry and ticagrelor antiplatelet effects were measured with up to three different platelet function tests: vasodilator-stimulated phosphoprotein phosphorylation assay, multiple electrode aggregometry and VerifyNow. The pharmacokinetic and pharmacodynamic assessment was performed in 70 patients (35 in each study group). Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0–12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0–12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004). Multiple regression analysis showed that lower AUC(0–12) values for ticagrelor were independently associated with the administration of morphine (P = 0.004) and the presence of ST-segment elevation myocardial infarction (P = 0.014). All three methods of platelet reactivity assessment showed a stronger antiplatelet effect in the placebo group and a greater prevalence of high platelet reactivity in patients receiving morphine. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction. ClinicalTrials.gov Identifier: NCT02217878.

6 November 2013 in BMJ
Verified
Journal Article
Open access
ENEliano Navarese
Eliano Navarese
KTK. Tandjung
K. Tandjung
BCBimmer Claessen
Bimmer Claessen
FAF. Andreotti
F. Andreotti
MKM. Kowalewski
M. Kowalewski
EKElvin Kedhi
Elvin Kedhi
F1000Prime Recommended Article: Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis.

29 April 2014 in European Heart Journal
Verified
Journal Article
Open access
PDF file
GMGilles Montalescot
Gilles Montalescot
BPBertram Pitt
Bertram Pitt
ESEsteban Lopez de Sa
Esteban Lopez de Sa
CHChristian W. Hamm
Christian W. Hamm
MFMarcus Flather
Marcus Flather
DSDavid Smith
David Smith
We aimed to assess the impact of eplerenone on cardiovascular (CV) outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset. In this randomized, placebo-controlled, double-blind trial, we assigned 1012 patients with acute STEMI and without a history of heart failure to receive either eplerenone (25–50 mg once daily) or placebo in addition to standard therapy. The primary endpoint was the composite of CV mortality, re-hospitalization, or, extended initial hospital stay, due to diagnosis of HF, sustained ventricular tachycardia or fibrillation, ejection fraction ≤40%, or elevated BNP/NT-proBNP at 1 month or more after randomization. BNP elevation was defined as BNP levels or values above 200 pg/mL or NT-proBNP values above 450 pg/mL (in patients aged below 50); above 900 pg/mL (age 50–75 years) or above 1800 pg/mL (patients older than 75). After a mean follow-up of 10.5 months, the primary endpoint occurred in 92 patients (18.2%) in the eplerenone group and in 149 patients (29.4%) in the placebo group [adjusted hazard ratio (HR), 0.58; 95% confidence interval (CI), 0.45–0.76; P < 0.0001]. The primary endpoint was driven by a high BNP/NT-proBNP level (adjusted HR, 0.60; 95% CI, 0.45–0.79; P < 0.0003). Adverse event rates were similar in both groups. Serum potassium levels exceeded 5.5 mmol/L in 5.6 vs. 3.2% (P = 0.09) and were below 3.5 mmol/L in 1.4 vs. 5.6% of patients (P = 0.0002), in the eplerenone and placebo groups, respectively. The addition of eplerenone during the acute phase of STEMI was safe and well tolerated. It reduced the primary endpoint over a mean 13 months follow-up mostly because of significantly lower BNP/NT-proBNP levels. Additional studies are needed to clarify the role of early use of MRAs in STEMI patients without heart failure. NCT01176968.